At a glance
ClinicalIndex Comparison RecordN/ACompleted· 823 enrolled
Drug / intervention
fesoterodinedrug
Likely dose
fesoterodine 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study In Patients With Overactive Bladder (OAB) Treated With Toviaz® After Failure Of Previous Antimuscarinic Therapy Due To Ineffectivity Or Intolerance.
In Brief
An observational study evaluating fesoterodine for Overactive Bladder and Urinary Incontinence. Completed, enrolled 823 participants across 65 sites.
Detailed Summary
This is a observational study in patients treated with fesoterodine (Toviaz), who have failed on previous treatment for overactive bladder. It will collect epidemiological data and investigate the efficacy and tolerability of fesoterodine.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder, Urinary Incontinence
CountriesSlovakia
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2008
Primary CompletionJun 2009
TodayJul 2026
First PostedJun 5, 2008
Enrollment StartJul 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.1 years ago
Interventions
fesoterodinedrug
4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment